In a new, proof-of-concept study, pioglitazone has been shown to lessen the metabolic and histologic abnormalities associated with nonalcoholic steatohepatitis (NASH), for which there is currently ...

Researchers at Georgetown University have developed a new drug called CTPI-2, which targets a key gene known as Slc25a1. This ...